243 related articles for article (PubMed ID: 24325739)
21. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer.
Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD
Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861
[TBL] [Abstract][Full Text] [Related]
22. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
Cells; 2020 May; 9(5):. PubMed ID: 32408542
[TBL] [Abstract][Full Text] [Related]
23. Characterization of CD133+ parenchymal cells in the liver: histology and culture.
Yoshikawa S; Zen Y; Fujii T; Sato Y; Ohta T; Aoyagi Y; Nakanuma Y
World J Gastroenterol; 2009 Oct; 15(39):4896-906. PubMed ID: 19842219
[TBL] [Abstract][Full Text] [Related]
24. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
[TBL] [Abstract][Full Text] [Related]
25. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
26. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
27. Biologic characteristics of the side population of human small cell lung cancer cell line H446.
Wang B; Yang H; Huang YZ; Yan RH; Liu FJ; Zhang JN
Chin J Cancer; 2010 Mar; 29(3):254-60. PubMed ID: 20193106
[TBL] [Abstract][Full Text] [Related]
28. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
[TBL] [Abstract][Full Text] [Related]
29. A robust culture method for maintaining tumorigenic cancer stem cells in the hepatocellular carcinoma cell line Li-7.
Sato Y; Yamada T; Hiroyama T; Sudo K; Hasegawa N; Hyodo I; Nakamura Y
Cancer Sci; 2019 May; 110(5):1644-1652. PubMed ID: 30784169
[TBL] [Abstract][Full Text] [Related]
30. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling.
Tang KH; Ma S; Lee TK; Chan YP; Kwan PS; Tong CM; Ng IO; Man K; To KF; Lai PB; Lo CM; Guan XY; Chan KW
Hepatology; 2012 Mar; 55(3):807-20. PubMed ID: 21994122
[TBL] [Abstract][Full Text] [Related]
31. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
32. Arsenite inhibits the function of CD133
Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
[TBL] [Abstract][Full Text] [Related]
33. [Expression of CD90/EpCAM/CD24 in hepatocellular carcinoma cell lines at various stages of differentiation].
Chen BD; Hui YF; Zhang HB; Fan LF; Si MH; Yang GS
Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):688-91. PubMed ID: 24160345
[TBL] [Abstract][Full Text] [Related]
34. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
35. Surface markers of hepatocellular cancer stem cells and their clinical potential.
Feng D; Wang N; Hu J; Li W
Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843
[TBL] [Abstract][Full Text] [Related]
36. High CD133 expression levels in gastrointestinal stromal tumors.
Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
[TBL] [Abstract][Full Text] [Related]
37. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
[TBL] [Abstract][Full Text] [Related]
38. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S
Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609
[TBL] [Abstract][Full Text] [Related]
39. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
[TBL] [Abstract][Full Text] [Related]
40. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon.
Kim HM; Haraguchi N; Ishii H; Ohkuma M; Okano M; Mimori K; Eguchi H; Yamamoto H; Nagano H; Sekimoto M; Doki Y; Mori M
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S539-48. PubMed ID: 21879266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
